News | Heart Failure | July 13, 2017

Biotronik Hosts Heart Failure Symposium at Europace-Cardiostim 2017

Studies highlight questions on avoiding ICD therapy, rate-adaptive pacing and the role of home monitoring

Biotronik Hosts Heart Failure Symposium at Europace-Cardiostim 2017

July 13, 2017 — Experts in heart failure management gathered in June to discuss varying scientific evidence in their field and how to transfer results into clinical practice. The Biotronik symposium “CRT in 2017: Remaining Challenges and New Opportunities in Heart Failure Management” took place at the Europace-Cardiostim 2017 congress, June 18-21 in Vienna, Austria.

One challenge is the limited data on whether to exchange cardiac resynchronization therapy defibrillators (CRT-Ds) for pacemakers (CRT-Ps) during routine device replacements in patients who responded well to therapy with improved hemodynamics. Jacques Mansourati, M.D., University of Western Brittany, Brest, France, is using the BioContinue study to help define the profile of CRT responders who may no longer need an implantable cardioverter defibrillator (ICD).

Between 20 to 40 percent of CRT patients suffer from chronotropic incompetence, representing a potentially high need for rate-adaptive pacing. At the same time, there is a lack of evidence about the effectiveness of accelerometer rate adaption — current guidelines do not include a recommendation. Mattias Roser, M.D., Charité Hospital, Berlin, Germany, is conducting a pilot study to research if rate-adaptive pacing with Closed Loop Stimulation (CLS) improves clinical outcomes. The primary endpoint is ventilatory efficiency – a cardio-pulmonary exercise test’s most reliable prognostic variable.

“Although available for decades, there is still conflicting evidence on whether an accelerometer, which measures patients’ movements, is clinically beneficial,” explained Roser. “We believe that CLS has the potential to significantly improve CRT patient outcomes as it reflects individual metabolic demand and reacts to the heart’s contractility. CLS from Biotronik is the only technology to respond to mental as well as physical stress.”

Physicians also discussed the benefits of Biotronik Home Monitoring for CRT patients. Guidelines recommend remote monitoring since the IN-TIME study demonstrated a significant reduction in mortality with Home Monitoring. Interestingly, when the Biotronik system was excluded from trials, such as REM-HF, More-CARE and Opti-Link HF, no clinical benefits of remote monitoring were found. The differences in study results can be explained by Home Monitoring’s features, according to the company: a multi-parameter analysis of relevant clinical data and highly-reliable daily data transfer. With efficient in-clinic workflow, Home Monitoring can prevent heart failure progression and reduce mortality as demonstrated by Hindricks et. al in the recent TRUECOIN meta-analysis.

For more information:

Related Content

CardiAMP Heart Failure Trial Design Presented at Texas Heart Institute Symposium
News | Heart Failure| September 25, 2017
BioCardia Inc. announced the trial design for its pivotal Phase III CardiAMP Heart Failure Trial was presented during...
Abbott Secures FDA Approval for MRI Compatibility on Ellipse ICD
Technology | Implantable Cardioverter Defibrillator (ICD)| September 22, 2017
Abbott announced U.S. Food and Drug Administration (FDA) approval for magnetic resonance (MR)-conditional labeling for...
MyoKardia Presents Additional Positive Data From Phase 2 PIONEER-HCM Study at HFSA 2017
News | Heart Failure| September 21, 2017
MyoKardia Inc. announced that additional positive data from the first patient cohort of its Phase 2 PIONEER-HCM study...
Heart Failure Market to Surpass $16 Billion by 2026
News | Heart Failure| September 19, 2017
The heart failure space across the seven key markets of the U.S., France, Germany, Italy, Spain, the U.K. and Japan is...
Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System
Technology | Hemodynamic Monitoring Systems| September 18, 2017
Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its...
Technavio Projects 9 Percent Global Growth for Electrophysiology Therapeutic Devices

Image courtesy of Technavio

News | EP Lab| September 11, 2017
September 11, 2017 — According to the latest market study released by Technavio, the global...
Heart Failure Patients, Clinicians Have Differing Perceptions of Risk Level
News | Heart Failure| September 06, 2017
September 6, 2017 — Physicians identified a majority of patients with advanced...
Israeli Hospital Completes First Implant of CORolla Heart Failure Device
News | Heart Failure| September 05, 2017
Rambam Hospital in Haifa, Israel, recently became the first to use the CORolla device from Israeli start-up company...
EMANATE Trial Shows Apixaban Lowers stroke in AF Patients Undergoing Cardioversion.
News | Atrial Fibrillation| September 01, 2017
September 1, 2017 — Apixaban lowers the risk of stroke compared to warfarin in anticoagulation-naïve patients with at
Overlay Init